Longevity Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–2 of 2 articles
Earlier
High impact AnalysisJun 2, 2026
STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
8 min
Dr. Sarah MitchellHigh impact AnalysisJun 2, 2026
Retro Biosciences Secures $1.8 Billion Valuation in Landmark Longevity Funding Round
FDA · longevity · 10 min
Dr. Sarah MitchellExplore intelligence